HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: CJN.03930907v1 3/3/829    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Leca, N. Articles by Davis, C. L. PubMed PubMed Citation Articles by Leca, N. Articles by Davis, C. L. Related Collections Related Article

Higher Levels of Leflunomide Are Associated with Hemolysis and Are not Superior to Lower Levels for BK Virus Clearance in Renal Transplant Patients

Nicolae Leca^*, Kimberly A. Muczynski^*, Jonathan A. Jefferson^*, Ian H. de Boer^*, Jolanta Kowalewska, Elizabeth A. Kendrick^*, Raimund Pichler^*, and Connie L. Davis^*

^* Department of Medicine, Division of Nephrology, and Department of Pathology, University of Washington, Seattle, Washington

Correspondence: Dr. Nicolae Leca, University of Washington Medical Center, 1959 NE Pacific Street, Box 356521, Seattle, WA 98195. Phone: 206-543-0690; Fax: 206-685-8661; E-mail: nleca{at}u.washington.edu

Background and objectives: Leflunomide use in renal transplantation has been increasing. Outcome correlation and safety data are still to be refined. The goals of this study were to report one center's experience with leflunomide, specifically the correlation of leflunomide levels with the outcomes of BK nephropathy and the observed toxic effects during the treatment with leflunomide.

Design, setting, participants, & measurements: Leflunomide was used in 21 patients with BK nephropathy. These patients were divided into two groups on the basis of the leflunomide levels achieved: Low-level group (<40 µg/ml) and high-level group (>40 µg/ml).

Results: During 13 mo of follow-up, there was no difference in the rate of serum BK viral clearance between the groups. There were three graft losses in the low-level group and one in the high-level group; however, creatinine levels were higher at the time of starting leflunomide in the low-level group. Leflunomide was also used in six patients with chronic allograft injury. No graft loss was observed during the follow-up period of 16 mo. Treatment with leflunomide seemed to be associated with a new toxicity, hemolysis, seen in four of the 27 patients so treated. Patients with hemolysis had high leflunomide levels (81.4 ± 14 µg/ml) and worsening allograft function. Two patients had histologic evidence of thrombotic microangiopathy, which led to graft loss in one patient.

Conclusions: The clinical correlation between leflunomide levels and outcomes needs to be further refined. This study described a possible association of leflunomide with thrombotic microangiopathy, especially at higher levels.

Related Article

Leflunomide Therapy in Kidney Transplantation: Ready for Prime Time?

Roslyn B. Mannon
Clin. J. Am. Soc. Nephrol. 2008 3: 652-653. [Full Text] [PDF]

This article has been cited by other articles:

				R. B. Mannon Leflunomide Therapy in Kidney Transplantation: Ready for Prime Time? Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 652 - 653. [Full Text] [PDF]